Independent research on the U.S. markets, Baptista Research

Baptista Research

Independent research on the U.S. markets

Baptista Research is an independent financial research house focused on the U.S. markets. We provide equity research as well as credit research reports on the top-listed U.S. companies with most of our focus on technology, consumer goods and services, automobiles, industrials, oil and gas, pharma, and healthcare. Our research has served more than 3000 institutional investors including mutual funds, hedge funds, banks, family offices, and various buy-side firms. We operate a research subscription service where institutions, as well as retail investors, can have priority access to all our research. We also have a wide distribution of our research reports across some of the top global financial platforms. Apart from equity research and credit research, we also provide advisory services with respect to mergers & acquisitions (M&A), private equity/ venture capital fundraising, valuation reports, and investment management services for corporates.
Baptista Research is owned and managed by Ishan Majumdar, an ex-Venture Capitalist/ Investment Banker, a Chartered Accountant, and a Masters’ degree holder in Management from HEC Paris. Ishan has nearly a decade of experience in Mergers and Acquisitions, Leveraged Buyouts (LBOs), Venture Capital Investing, Corporate Strategy, and Valuation in front-office roles at the likes of BNP Paribas CIB, Credit Agricole CIB, Groupe Danone, and TIW Private Equity. He has worked on and closed multiple acquisition deals, leveraged buyouts, and start-up investment transactions.

Equity Bottom-Up

GE HealthCare Technologies  / Equity Bottom-Up

<ul><li>GE HealthCare has moved to deepen its position in molecular imaging through a $945 million cash agreement to acquire Sofie Biosciences from Trilantic North America, with closing expected in the first half of 2027.</li><li>Sofie manufactures PET radiopharmaceuticals and operates a U.S. production network for short-lived radioactive tracers, giving GE HealthCare access to the time-sensitive final mile of radiopharmaceutical delivery.</li><li>The deal also adds a pipeline that includes diagnostic agents targeting gastroesophageal and pancreatic cancers and is intended to sit within GE HealthCare’s Pharmaceutical Diagnostics segment.</li></ul>

GE HealthCare has moved to deepen its position in molecular imaging through a $945 million cash agreement to acquire Sofie Biosciences from Trilantic North America, with closing expected in the first half of 2027.Sofie manufactures PET radiopharmaceuticals and operates a U.S. production network for short-lived radioactive tracers, giving GE HealthCare access to the time-sensitive final mile of radiopharmaceutical delivery.The deal also adds a pipeline that includes diagnostic agents targeting gastroesophageal and pancreatic cancers and is intended to sit within GE HealthCare’s Pharmaceutical Diagnostics segment.

GE HealthCare Acquisition: The $945M Sofie Bet That Could Reshape PET Imaging!

<ul><li>GE HealthCare is reportedly in advanced talks to acquire radiopharmaceutical developer Sofie Biosciences for roughly $1 billion, a transaction that could deepen the medical-imaging company’s push beyond selling scanners and toward earning more revenue from what happens every time those machines are used.</li><li>The deal has not been finalized and negotiations could still change or collapse, according to the latest reports.</li><li>Sofie develops radioactive diagnostic agents used in PET scans and operates the specialized production infrastructure required to manufacture and distribute them.</li></ul>

GE HealthCare is reportedly in advanced talks to acquire radiopharmaceutical developer Sofie Biosciences for roughly $1 billion, a transaction that could deepen the medical-imaging company’s push beyond selling scanners and toward earning more revenue from what happens every time those machines are used.The deal has not been finalized and negotiations could still change or collapse, according to the latest reports.Sofie develops radioactive diagnostic agents used in PET scans and operates the specialized production infrastructure required to manufacture and distribute them.

GE HealthCare’s Potential $1 Billion Cancer Bet Could Transform Its Business!

Smartkarma AI Primers, Smartkarma

αSK Primers

Smartkarma AI Primers

Smartkarma

Smartkarma unites the fragmented investment industry, connecting institutional investors, independent research providers, and corporates within a single network.

Research Reinvented

<ul>
  <li>GE HealthCare is a global leader in medical imaging and diagnostics, well-positioned to benefit from long-term secular trends such as aging populations and the increasing prevalence of chronic diseases.</li>
  <li>The company's strategy is centered on 'Precision Care,' leveraging its large installed base, recurring service revenues, and significant investments in AI and digital solutions to improve diagnostics and workflow efficiency.</li>
  <li>While facing intense competition, supply chain challenges, and operational issues in its Patient Care Solutions segment, the company's strong orders growth and record backlog provide good forward visibility, though margin execution remains a key focus.</li>
</ul><p><em>This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.</em></p>


  GE HealthCare is a global leader in medical imaging and diagnostics, well-positioned to benefit from long-term secular trends such as aging populations and the increasing prevalence of chronic diseases.
  The company's strategy is centered on 'Precision Care,' leveraging its large installed base, recurring service revenues, and significant investments in AI and digital solutions to improve diagnostics and workflow efficiency.
  While facing intense competition, supply chain challenges, and operational issues in its Patient Care Solutions segment, the company's strong orders growth and record backlog provide good forward visibility, though margin execution remains a key focus.
This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.

Primer: GE HealthCare Technologies  (GEHC US) - Aug 2026

<ul><li>General Electric HealthCare reported its financial results for the fourth quarter and full year 2025 with organic revenue growth outpacing expectations, supported by strong demand in the U.S. and Europe, Middle East, and Africa (EMEA) regions.</li><li>The company recorded a 4.8% organic revenue increase in the quarter, driven largely by Pharmaceutical Diagnostics (up double digits) and mid-single-digit growth in Imaging and Advanced Visualization Solutions.</li><li>Product and service revenues both grew, with product revenue up 7.9% and service revenue by 5.5%.</li></ul>

General Electric HealthCare reported its financial results for the fourth quarter and full year 2025 with organic revenue growth outpacing expectations, supported by strong demand in the U.S. and Europe, Middle East, and Africa (EMEA) regions.The company recorded a 4.8% organic revenue increase in the quarter, driven largely by Pharmaceutical Diagnostics (up double digits) and mid-single-digit growth in Imaging and Advanced Visualization Solutions.Product and service revenues both grew, with product revenue up 7.9% and service revenue by 5.5%.

General Electric Healthcare: China Weakness, Stronger Execution—Is A Turnaround Already Underway?

<ul><li>GE HealthCare Technologies is moving deeper into the software space with its planned $2.3 billion acquisition of Intelerad, a Montreal-based provider of enterprise imaging software.</li><li>As the healthcare landscape shifts toward outpatient and ambulatory settings, this acquisition signals GE HealthCare’s strategic push to diversify beyond its traditional inpatient stronghold.</li><li>Intelerad’s platform includes radiology PACS, cloud-based image sharing, and workflow solutions, which could dovetail with GE’s diagnostic imaging portfolio.</li></ul>

GE HealthCare Technologies is moving deeper into the software space with its planned $2.3 billion acquisition of Intelerad, a Montreal-based provider of enterprise imaging software.As the healthcare landscape shifts toward outpatient and ambulatory settings, this acquisition signals GE HealthCare’s strategic push to diversify beyond its traditional inpatient stronghold.Intelerad’s platform includes radiology PACS, cloud-based image sharing, and workflow solutions, which could dovetail with GE’s diagnostic imaging portfolio.

GE HealthCare’s $2.3 Billion Acquisition Of Intelerad: Game-Changer Or Growing Pains?

United States

GE HealthCare Technologies Inc. provides medical technology, pharmaceutical diagnostics, and digital solutions. The Company offers imaging, ultrasound, maternal, ventilator, and patient monitoring equipment, as well as performance management, cybersecurity, technical training, site planning, integrated asset optimization, and clinical network solutions.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

GE HealthCare Technologies (GEHC US)

GE HealthCare Acquisition: The $945M Sofie Bet That Could Reshape PET Imaging!

GE HealthCare has moved to deepen its position in molecular imaging through a $945 million cash agreement to acquire Sofie Biosciences from...

Baptista Research

GE HealthCare’s Potential $1 Billion Cancer Bet Could Transform Its Business!

GE HealthCare is reportedly in advanced talks to acquire radiopharmaceutical developer Sofie Biosciences for roughly $1 billion, a transaction...

Baptista Research

Primer: GE HealthCare Technologies (GEHC US) - Aug 2026

GE HealthCare is a global leader in medical imaging and diagnostics, well-positioned to benefit from long-term secular trends such as aging...

αSK Primers

General Electric Healthcare: China Weakness, Stronger Execution—Is A Turnaround Already Underway?

General Electric HealthCare reported its financial results for the fourth quarter and full year 2025 with organic revenue growth outpacing...

Baptista Research

GE HealthCare’s $2.3 Billion Acquisition Of Intelerad: Game-Changer Or Growing Pains?

GE HealthCare Technologies is moving deeper into the software space with its planned $2.3 billion acquisition of Intelerad, a Montreal-based...

Baptista Research

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)